Previously recorded as Metabolex, Inc. (to 2013)
28 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
15 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Dec 2027
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2035 · High confidence
Also notable
Ends Dec 2027 · High confidence
Also notable
Ends Mar 2035 · High confidence
Also notable
Ends Aug 2033 · High confidence
Also notable
Ends Jul 2038 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Oct 2029 · High confidence
Treatment of NAFLD and NASH
US 9,381,181
The most cited patent in this portfolio, cited by 155 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2035.
5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE
US 7,638,541
Cited by 64 later US patents, top 25% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Treatment of Intrahepatic Cholestatic Diseases
US 9,486,428
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2035.
Bicyclic Agonists of GPR131 and Uses Thereof
US 9,593,109
Cited by 25 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Treatment of intrahepatic cholestatic diseases
US 10,512,622
Granted 2019. Computed term ends 2038.
Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE
US 9,241,924
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2031.
Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts
US 9,150,567
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Methods of Reducing Small, Dense LDL Particles
US 11,007,162
Granted 2021. Computed term ends 2029. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Treatment of NAFLD and NASH (US 10,342,770) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts (US 9,150,567) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Treatment of intrahepatic cholestatic diseases (US 10,478,411) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Treatment of intrahepatic cholestatic diseases (US 10,512,622) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 26, 2027The maintenance fee for Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE (US 9,241,924) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 21, 2026
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Treatment of Intrahepatic Cholestatic Diseases | 10 in force | to Mar 2035 |
| Treatment of NAFLD and NASH | 7 in force | to Apr 2035 |
| Treatment of intrahepatic cholestatic diseases | 3 in force | to Jul 2038 |
| 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE | 3 in force | to May 2028 |
| Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE | 1 in force | to Oct 2031 |
| Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts | 1 in force | to Sep 2030 |
| Methods of Reducing Small, Dense LDL Particles | 1 in force | to Oct 2029 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,638,541 | 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE In force · High confidence | In force | High confidence | |
| US 8,921,350 | Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders In force · Medium confidence | In force | Medium confidence | |
| US 8,975,258 | Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders In force · Medium confidence | In force | Medium confidence | |
| US 11,007,162 | Methods of Reducing Small, Dense LDL Particles In force · High confidence | In force | High confidence | |
| US 9,150,567 | Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts In force · High confidence | In force | High confidence | |
| US 9,241,924 | Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE In force · High confidence | In force | High confidence | |
| US 8,703,776 | Agonists of GPR131 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,593,109 | Bicyclic Agonists of GPR131 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,486,428 | Treatment of Intrahepatic Cholestatic Diseases In force · High confidence | In force | High confidence | |
| US 9,808,436 | Treatment of Intrahepatic Cholestatic Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 28: 51 patents ended · 8 applications pending · 24 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.